ReNerve Limited has entered a strategic partnership with Berkeley Biologics to develop and commercialise two new tissue-based product ranges, aiming to expand its footprint in the US surgical market by the end of 2025.
ReNerve Limited has gained marketing approval for its NervAlign® Nerve Cuff™ in Bahrain, marking its first regulatory success in the Middle East and opening access to a rapidly expanding regional market.